Trametinib

Generic Name
Trametinib
Brand Names
Mekinist, Spexotras
Drug Type
Small Molecule
Chemical Formula
C26H23FIN5O4
CAS Number
871700-17-3
Unique Ingredient Identifier
33E86K87QN
Background

Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...

Indication

Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

It is used in combination with dabrafenib for the:
...

Associated Conditions
Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
Associated Therapies
-
Clinical Trials
Related News

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

First Posted Date
2014-01-06
Last Posted Date
2019-05-17
Lead Sponsor
MedImmune LLC
Target Recruit Count
68
Registration Number
NCT02027961
Locations
🇮🇹

Research Site, Napoli, Italy

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

First Posted Date
2013-12-20
Last Posted Date
2019-02-27
Lead Sponsor
Kartos Therapeutics, Inc.
Target Recruit Count
36
Registration Number
NCT02016729
Locations
🇺🇸

Research Site, Seattle, Washington, United States

Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

First Posted Date
2013-12-19
Last Posted Date
2024-10-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
10
Registration Number
NCT02015117
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

First Posted Date
2013-11-21
Last Posted Date
2024-11-15
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
75
Registration Number
NCT01989585
Locations
🇺🇸

University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States

and more 46 locations

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

First Posted Date
2013-11-21
Last Posted Date
2024-10-01
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
45
Registration Number
NCT01990196
Locations
🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

First Posted Date
2013-11-21
Last Posted Date
2022-03-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
25
Registration Number
NCT01989598
Locations
🇨🇦

University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

and more 2 locations

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

First Posted Date
2013-11-08
Last Posted Date
2020-02-24
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
42
Registration Number
NCT01979523
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇫🇷

Institut Curie Paris, Paris, France

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

and more 4 locations

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

Phase 2
Active, not recruiting
Conditions
Melanoma
Interventions
Drug: Dabrafenib
Drug: Trametinib
First Posted Date
2013-10-30
Last Posted Date
2023-08-30
Lead Sponsor
Melanoma Institute Australia
Target Recruit Count
35
Registration Number
NCT01972347
Locations
🇦🇺

Melanoma Institute Australia, North Sydney, New South Wales, Australia

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

First Posted Date
2013-10-17
Last Posted Date
2019-09-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
37
Registration Number
NCT01964924
Locations
🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

🇺🇸

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 5 locations

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

First Posted Date
2013-09-12
Last Posted Date
2022-03-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
15
Registration Number
NCT01940809
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy